Abstract
Legend Biotech will report second-quarter results on August 11, 2026 Pre-MKt; consensus points to accelerating top-line momentum alongside a return toward operating profitability, with the market focused on the durability of CARVYKTI-driven collaboration revenue and the company’s execution through a leadership transition.Market Forecast
Market expectations for the current quarter center on revenue of 355.77 million US dollars, up 55.36% year over year, with EBIT projected at 31.23 million US dollars, up 172.82% year over year, and EPS near 0.08 US dollars, up 152.37% year over year. Forecasts do not specify a gross margin or net margin figure for this quarter, but point to a continued revenue ramp as collaboration economics from CARVYKTI scale.The main revenue line remains licensing and collaboration revenue tied primarily to CARVYKTI; last quarter’s collaboration revenue was 305.10 million US dollars, up 56.42% year over year, and the company’s outlook emphasizes sustained uptake and broader site activation. The highest-potential growth vector is the CARVYKTI franchise itself, with partner-reported net trade sales of approximately 657.00 million US dollars in the quarter ended June 30, 2026, up 49.40% year over year, underpinning higher collaboration revenue recognition at Legend Biotech as the therapy penetrates more treatment settings and geographies.
Last Quarter Review
In the prior quarter, Legend Biotech delivered revenue of 305.10 million US dollars (up 56.42% year over year), a gross profit margin of 42.35%, GAAP net loss attributable to shareholders of 54.30 million US dollars with a net profit margin of −17.80% and a quarter-on-quarter change in net profit of −76.21%, and adjusted EPS of −0.30 (up 44.44% year over year).One notable development was the continued scaling of the CARVYKTI commercial base, which, according to partner disclosures, saw robust demand that fed into higher collaboration revenue recognition for Legend Biotech. Main business highlights were concentrated in licensing and collaboration, which accounted for 305.10 million US dollars in revenue, up 56.42% year over year, reflecting stronger partner sales and expanded global site availability.
Current Quarter Outlook (with major analytical insights)
Licensing and Collaboration Revenue from the CARVYKTI Franchise
Legend Biotech’s core revenue driver this quarter remains licensing and collaboration income from CARVYKTI commercial performance. Partner-reported net trade sales reached approximately 657.00 million US dollars in the quarter ended June 30, 2026, up 49.40% year over year, giving clear line-of-sight to higher collaboration revenue recognition in the current print. The company’s projection embedded in market estimates implies 355.77 million US dollars of total revenue for the quarter, a 55.36% year-over-year rise, consistent with continued global expansion and deeper penetration into community oncology settings.Operationally, CARVYKTI availability continues to increase, with the commercial network cited as spanning 14 markets and 294 sites as of the most recent updates earlier this year. That footprint matters because cell therapy adoption is strongly correlated with site onboarding, manufacturing reliability, and patient throughput; management commentary points to improved manufacturing success rates and fewer logistical bottlenecks compared with the early launch phase. On the financial side, collaboration accounting tends to lag sell-in and can be influenced by milestones, profit-share mechanics, and inventory movements; even so, the breadth of partner net trade sales has historically translated into robust top-line growth for Legend Biotech, aligning with consensus expectations for a mid-50s percent year-over-year revenue increase this quarter.
Margin implications are more nuanced. While last quarter’s gross margin was 42.35%, quarter-to-quarter movement may depend on mix, recognition timing within the collaboration framework, and ongoing R&D investment cadence. The EBIT inflection implied by consensus (31.23 million US dollars, up 172.82% year over year) suggests operating leverage from scaling collaboration revenue, even as the company invests in expanding commercial support and next-generation pipeline programs. EPS near 0.08 US dollars, if achieved, would signal a marked improvement from the adjusted loss in the prior quarter and indicate momentum toward the company’s previously discussed timeline for operating profitability.
Next-Generation Pipeline with Emphasis on In Vivo CAR-T (LB2501)
The most closely watched innovation catalyst is the in vivo CAR-T program LB2501, which has shown early clinical proof-of-concept in relapsed or refractory B-cell non-Hodgkin lymphoma. At the higher dose tested in an ongoing phase 1 trial, a single infusion delivered a 100% objective response rate and an 83.3% complete response rate in six patients, while across both dose levels the objective and complete response rates were 50% and 41.7%, respectively, with a favorable safety profile and no dose-limiting toxicities or neurotoxicity observed. This matters to the current quarter not because it contributes revenue today, but because meaningful de-risking in next-generation cell therapy can sustain investor confidence through near-term volatility and support capital access, partnership optionality, and long-term earnings power.Analysts have highlighted the structural advantages of in vivo approaches, including the potential for on-demand, off-the-shelf administration without the delays and costs of ex vivo manufacturing. A recent analyst note argued that, if development proceeds expeditiously, first market entry could be achievable around 2029 in certain indications and that non-Hodgkin lymphoma alone may represent a 3.00 billion US dollar opportunity for this modality. From a financial modeling perspective, while this pipeline will not influence the collaboration revenue line in the imminent quarter, it can affect the valuation framework and risk premium applied to Legend Biotech’s shares. Progress updates and clarity on dose expansion cohorts could be a swing factor for sentiment as investors calibrate how much of a second growth engine is being discounted.
The interplay between current CARVYKTI cash flows and longer-dated pipeline spend is another point of emphasis. Management recently bolstered the balance sheet with a public ADS offering that raised approximately 226.00 million US dollars in June, which, in combination with improving EBIT dynamics, provides flexibility to fund dose expansions, manufacturing scale-up planning for next-generation assets, and potential business development. In this sense, LB2501’s early signals reinforce a framework in which the CARVYKTI collaboration finances pipeline progression, with valuation upside tied to successful translation of in vivo results into larger, controlled studies.
Stock Price Drivers This Quarter: Leadership Transition, Competitive Messaging, and Execution
The stock’s near-term performance is likely to be influenced by management transition headlines, competitive narratives in multiple myeloma, and delivery against consensus on revenue and profitability. On July 24, 2026, Legend Biotech announced that its Chief Executive Ying Huang stepped down from the board and the company appointed Alan Bash, president of the CARVYKTI business unit, as Interim CEO. Such transitions can prompt a risk premium reset, but markets generally refocus on execution milestones; in the same period, analysts continued to emphasize the operational strength of CARVYKTI and the strategic importance of the in vivo pipeline, mitigating leadership uncertainty in their outlooks.Competitive messaging in the BCMA treatment landscape remains a watchpoint, particularly as alternative regimens from large-cap peers emphasize convenience and combination potential. Even so, the company’s commentary has underlined that uptake in community settings remains early, with room for share expansion as site activation and physician familiarity grow. Importantly, CARVYKTI’s one-time therapy profile and emerging durability data have resonated with prescribers, underpinning the acceleration seen in partner-reported net trade sales and feeding through to collaboration revenue at Legend Biotech.
Consensus is sensitive to execution signals: achieving or exceeding the 355.77 million US dollar revenue estimate and delivering on the 31.23 million US dollar EBIT estimate would reinforce the operating leverage thesis. Conversely, any flagging of site throughput, manufacturing, or channel inventory dynamics could weigh on short-term sentiment. The capital raise completed in June provides an additional buffer as the company navigates both the leadership change and continued R&D investment, while pipeline updates—especially any follow-up data on LB2501—could be incremental positives that offset headline noise.
Analyst Opinions
Recent published opinions are predominantly positive. Across coverage since February 2026, we observe at least six Buy or Outperform reiterations versus a single downgrade to Neutral, which sets a roughly 6:1 bullish-to-bearish ratio. Analysts cite strong CARVYKTI momentum, improving operating leverage, and the strategic potential of the in vivo CAR-T platform as the core pillars of the constructive view.RBC Capital Markets maintained an Outperform rating, arguing that the in vivo program’s early data “validates the approach,” with potential to enable higher peak potential and positing as much as a 3.00 billion US dollar opportunity in non-Hodgkin lymphoma alone if timelines advance efficiently; they recently adjusted their price target to 59 US dollars while keeping the positive stance. Barclays reiterated a Buy rating with an 80 US dollar target, emphasizing the continued scaling of CARVYKTI and the expanding global commercial footprint. Oppenheimer reaffirmed a Buy with a 75 US dollar target, pointing to robust partner-reported sales and the durability of the collaboration economics as reasons to expect upside versus mid-term consensus revenue trajectories.
Morgan Stanley maintained a Buy rating with a 49 US dollar target, focusing on execution and the near-term trajectory toward operating profitability as revenue grows into the collaboration framework. H.C. Wainwright reiterated a Buy with a 65 US dollar target, highlighting attractive valuation following share weakness and underscoring confidence in CARVYKTI demand patterns and operating leverage. Complementing these views, a widely circulated earnings preview summarized consensus for the current quarter as revenue of 355.77 million US dollars, EBIT of 31.23 million US dollars, and EPS of 0.08 US dollars, each implying triple-digit percentage growth for EBIT and EPS and a mid-50s percent increase in revenue year over year.
While there has been at least one notable counterpoint—UBS downgraded the stock to Neutral and reduced its target to 28 US dollars in late July amid leadership changes and competitive considerations—the balance of commentary remains supportive. The majority perspective stresses that the commercial performance of CARVYKTI, evidenced by partner-reported net trade sales of 657.00 million US dollars in the quarter ended June 30, 2026, and global site expansion, should drive continued collaboration revenue growth and operating leverage in the near term. Analysts also view LB2501 as a credible second act that can sustain long-term optionality, and they argue the June capital raise, alongside improving EBIT, provides financial flexibility to progress the pipeline without compromising commercial execution.
In aggregate, the majority view contends that Legend Biotech is positioned to meet or exceed this quarter’s consensus revenue and profitability expectations, with the primary sensitivities being the cadence of collaboration revenue recognition, any logistical variances in site throughput, and investor interpretation of leadership transition headlines. The constructive stance anticipates that delivery against the 355.77 million US dollar revenue estimate and demonstration of operating leverage will be sufficient to mitigate transient volatility from management changes and broader competitive narratives. As a result, bullish observers expect the print on August 11, 2026 Pre-MKt to reinforce the company’s path toward operating profitability and to keep the strategic spotlight on pipeline catalysts that can broaden the medium-term growth profile.
Comments